The House appropriations report for FDA takes a two-pronged approach to advising the agency how to exercise its oversight of compounding: take care with particular products to make sure patients are protected, but step back in other areas to make sure traditional compounding can be maintained.
Roche/Genentech Inc.’s degenerative eye disease treatment Lucentis (ranibizumab) could benefit from the Congressional instructions on a guidance that covers repackaging biological products outside a BLA
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?